A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Mature B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Rituximab
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche